Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy
Read More Pharma Industry News How does Amplia’s ACCENT trial compare to MPACT and POLO in pancreatic cancer response rates? Amplia’s pancreatic cancer trial hits a 31% response rate, surpassing MPACT. Find out how it compares to POLO and what it means for future therapy options. byPallavi MadhirajuJuly 17, 2025